Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given New $15.00 Price Target at HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) had its price objective hoisted by analysts at HC Wainwright from $9.00 to $15.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 62.16% from the stock’s current price.

Separately, JonesTrading started coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They set a “buy” rating and a $15.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN ARMP traded up $0.52 during trading hours on Monday, hitting $9.25. The company’s stock had a trading volume of 27,372 shares, compared to its average volume of 51,042. Armata Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $16.34. The stock has a market cap of $336.79 million, a price-to-earnings ratio of -5.71 and a beta of 1.42. The business has a 50-day simple moving average of $6.85 and a 200-day simple moving average of $5.17.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. 683 Capital Management LLC purchased a new position in Armata Pharmaceuticals in the 4th quarter worth approximately $878,000. Geode Capital Management LLC raised its stake in shares of Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock worth $690,000 after purchasing an additional 5,342 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after purchasing an additional 27,200 shares during the last quarter. State Street Corp lifted its holdings in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after purchasing an additional 10,500 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at $284,000. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.